Business Context and Reporting Period
West Pharmaceutical Services, Inc. filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2023. West manufactures containment, packaging and drug-delivery systems for injectable drugs and healthcare products and operates through Proprietary Products and Contract-Manufactured Products.
Net sales mix for the third quarter was approximately 40% biologics, 19% generics, 22% pharma and 19% contract-manufactured products. Geographic sales were approximately 46% Americas, 46% Europe/Middle East/Africa and 8% Asia Pacific.
Key Financial Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Net sales | $747.4 million | $686.9 million | $2,217.8 million | $2,178.2 million |
| Gross profit | $288.3 million | $268.0 million | $851.0 million | $874.1 million |
| Gross margin | 38.6% | 39.0% | 38.4% | 40.1% |
| Operating profit | $177.3 million | $186.2 million | $515.1 million | $604.3 million |
| Operating margin | 23.7% | 27.1% | 23.2% | 27.7% |
| Net income | $161.3 million | $120.6 million | $456.4 million | $482.9 million |
| Diluted EPS | $2.14 | $1.59 | $6.05 | $6.36 |
Third-quarter sales increased 8.8% as reported and 5.7% organically. Nine-month sales increased 1.8% as reported and 1.7% organically. Foreign currency translation benefited reported sales by $25.1 million in the quarter and $9.4 million for the nine-month period.
For the first nine months, operating cash flow was $537.4 million, compared with $493.2 million in the prior-year period. Capital expenditures were $253.3 million versus $189.7 million, primarily for additional manufacturing capacity. Free cash flow, calculated as operating cash flow less capital expenditures, was approximately $284.1 million.
At September 30, 2023, cash and cash equivalents were $898.6 million, working capital was $1,438.8 million and total debt was $207.3 million, including $55.2 million classified as current and $152.1 million classified as long-term. The $500.0 million revolving credit facility had $497.6 million of available borrowing capacity, including outstanding letters of credit, and had no outstanding borrowings. The company was in compliance with its debt covenants.
Material Changes Versus the Prior Comparable Period
- Third-quarter sales grew primarily from pricing, growth in high-value components and delivery devices, and stronger contract-manufactured volumes. Contract-Manufactured Products sales rose 20.8%, while Proprietary Products sales rose 6.3% as reported.
- Nine-month Proprietary Products sales declined 1.0%, principally because COVID-related sales fell approximately $272 million. This decline was partly offset by growth in high-value components and devices and price increases.
- Nine-month Contract-Manufactured Products sales increased 16.2%, driven by higher volumes of components for injection-related and diagnostic devices and pricing.
- Nine-month gross profit declined 2.6% and gross margin fell 170 basis points, reflecting the loss of higher-margin COVID-related sales, approximately $21 million less in net fees from COVID-19 supply agreements and inflationary compensation costs.
- Nine-month operating profit declined 14.8%, while SG&A increased 13.9% to $263.4 million. Higher incentive compensation, stock-based compensation mark-to-market expense and other compensation costs contributed to the increase.
- Net income increased in the third quarter but declined for the nine months. The prior-year period included a $49.6 million third-quarter and $50.8 million nine-month pension settlement charge, as well as related tax benefits, which distorts the year-over-year comparison.
Guidance, Outlook, Commentary and Risks
The filing does not provide clear quantitative full-year revenue or earnings guidance. Management stated that cash on hand, operating cash flow and revolver availability are expected to meet foreseeable liquidity needs based on current expectations for operations, capital expenditures and scheduled debt payments.
A December 2022 restructuring plan is expected to generate annualized savings of approximately $22 million to $24 million and require total charges of approximately $25 million to $27 million over up to 24 months. The remaining restructuring obligation was $5.6 million at September 30, 2023.
Management continues to invest in manufacturing capacity and research, including elastomeric packaging, glass systems, drug containment, self-injection and drug-administration products. The filing identifies demand for high-value products, customer product approvals and commercialization timing as important drivers of future performance.
Principal risks include the continuing decline in COVID-related demand, inflation and petroleum-based raw-material costs, supply-chain interruptions, reliance on third-party and single-source suppliers, foreign-exchange volatility, customer inventory changes, regulatory and commercialization delays, competition, labor availability and geopolitical developments. West has operations in Israel and stated that its facilities continued to substantially operate as before the conflict; it continues to monitor related risks. The company also added a risk factor concerning bank failures and potential difficulty accessing deposits or lending commitments.
Unusual items included an $11.6 million loss on the sale of a manufacturing facility, a $6.9 million asset-impairment charge, a $3.8 million favorable legal settlement benefit, and a $3.3 million impairment of a cost investment. The company stated that current legal proceedings are not expected to have a material adverse effect, and no significant changes to previously disclosed commitments and contingencies were reported.
Most Important Facts to Verify
- Whether the decline in COVID-related sales has stabilized and how quickly high-value products can replace lost higher-margin volume.
- The sustainability of pricing actions and production efficiencies relative to inflationary compensation, raw-material and supply-chain costs.
- The timing and return profile of the elevated capital expenditures for manufacturing capacity.
- Debt maturities, including the $55.2 million current portion, and the company’s ability to maintain covenant compliance.
- Progress and realized savings from the restructuring plan versus the projected $22 million to $24 million annualized savings.
- Exposure to foreign exchange, petroleum-derived elastomer costs, geopolitical developments and potential banking-system liquidity disruptions.
- The remaining authorization under the $1.0 billion share-repurchase program; approximately $738.7 million remained available at September 30, 2023.